Greenwich LifeSciences is a public clinical-stage biopharmaceutical company focused on developing an immunotherapy to prevent breast cancer recurrences in patients who have undergone surgery. Their lead product, GP2, is an immunotherapy derived from the HER2 neu protein expressed in breast cancer and other common cancers. Statistically significant Phase IIb clinical trial data has shown both safety and efficacy, with no cancer recurrences in HER2 neu positive breast cancer patients treated with GP2 after a median 5 years of follow-up.
Greenwich LifeSciences has commenced a Phase III clinical trial, Flamingo-01, designed to reproduce the Phase IIb results and continue saving lives. With a well-tolerated safety profile, the company aims to advance patient care by discovering and developing biotherapeutics.
Generated from the website